Alibaba Health Information revealed a groundbreaking move on Tuesday, announcing a strategic deal worth HK$13.51 billion ($1.73 billion) to acquire certain services of Alibaba’s marketing tool. The deal involves the purchase of AJK Technology Holding Ltd from Taobao Holding Limited, a unit of the renowned tech conglomerate Alibaba Group.
The acquisition is set to significantly impact Alibaba Health’s operations, providing the company with exclusive rights to specific services offered through Alibaba’s digital marketing tool, Alimama. This includes services aimed at supporting online merchants specializing in healthcare products, such as the verification of merchants’ marketing materials.
In a filing to the Hong Kong stock exchange, Alibaba Health expressed optimism about the deal’s potential to bolster both its revenue and the quality of services provided to online health stores. The transaction is expected to contribute to the company’s growth and profitability outlook, positioning it as a key player in the rapidly evolving e-commerce landscape.
As part of the agreement, Alimama will continue to offer its services to Alibaba Health, which will, in turn, pay fees for the services set to be operated under its umbrella post-transaction. This collaboration is anticipated to foster a synergistic relationship, benefiting both entities involved.
To facilitate the acquisition, Alibaba Health plans to issue 2.56 billion shares at HK$4.50 apiece and pay the U.S. dollar equivalent of HK$2 billion in cash to Taobao Holding. This financial arrangement underscores the strategic importance of the deal for both parties and highlights the commitment to the successful integration of services.
Alibaba Health’s move aligns with its overarching strategy to stay at the forefront of technological advancements in the healthcare sector. By leveraging Alibaba’s robust digital marketing capabilities, the company aims to enhance its ability to provide valuable services to online health stores, ultimately contributing to the broader ecosystem of digital healthcare.
The transaction awaits regulatory approvals and is subject to customary closing conditions. Once finalized, the deal is poised to reshape the landscape of online health commerce, bringing forth new possibilities for Alibaba Health Information and its stakeholders.